Small-field dosimetry of TrueBeamTM flattened and flattening filter-free beams: A multi-institutional analysis.

PURPOSE: Detector-dependent interinstitutional variations of the beam data may lead to uncertainties of the delivered dose to patients. Here we evaluated the inter-unit variability of the flattened and flattening filter-free (FFF) beam data of multiple TrueBeam (Varian Medical Systems) linear accelerators focusing on the small-field dosimetry. METHODS: The beam data of 6- and 10-MV photon beams with and without flattening filter measured for modeling of an iPLAN treatment planning system (BrainLAB) were collected from 12 institutions - ten HD120 Multileaf Collimator (MLC) and two Millennium120 MLC. Percent-depth dose (PDD), off-center ratio (OCR), and detector output factors (OFdet ) measured with different detectors were evaluated. To investigate the detector-associated effects, we evaluated the inter-unit variations of the OFdet before and after having applied the output correction factors provided by the International Atomic Energy Agency (IAEA) Technical Reports Series no. 483. RESULTS: PDD measured with a field size of 5 × 5 mm2 showed that the data measured using an ionization chamber had variations exceeding 1% from the median values. The maximum difference from median value was 2.87% for 10 MV photon beam. The maximum variations of the penumbra width for OCR with 10 × 10 mm2 field size were 0.97 mm. The OFdet showed large variations exceeding 15% for a field size of 5 × 5 mm2 . When the output correction factors were applied to the OFdet , the variations were greatly reduced. The relative difference of almost all field output factors were within ± 5% from the median field output factors. CONCLUSION: In this study, the inter-unit variability of small-field dosimetry was evaluated for TrueBeam linear accelerators. The variations were large at a field size of 5 × 5 mm2 , and most occurred in a detector-dependent manner.

Impact of detector selections on inter-institutional variability of flattening filter-free beam data for TrueBeam™ linear accelerators.

This study evaluates the type of detector influencing the inter-institutional variability in flattening filter-free (FFF) beam-specific parameters for TrueBeam™ linear accelerators (Varian Medical Systems,Palo Alto, CA, USA). Twenty-four beam data sets, including the percent depth dose (PDD), off-center ratio (OCR), and output factor (OPF) for modeling within the Eclipse (Varian Medical Systems) treatment planning system, were collected from 19 institutions. Although many institutions collected the data using CC13 (IBA Dosimetry, Schwarzenbruck, Germany) or PTW31010 semiflex (PTW Freiburg, Freiburg, Germany) ionization chambers, some institutions used diode detectors, diamond detectors, and ionization chambers with smaller cavities. The OCR data included penumbra width, full width at half maximum (FWHM), and FFF beam-specific parameters, including unflatness and slope. The data measured by CC13/PTW31010 ionization chambers were compared with those measured by all other detectors. PDD data demonstrated the variations within ±1% at the dose fall-off region deeper than peak depth. The penumbra widths of the OCR measured with the CC13/PTW31010 detectors were significantly larger than those measured with all other detectors (P < 0.05). Especially the EDGE detector (Sun Nuclear Corp., Melbourne, FL, USA) and the microDiamond detectors (model 60019; PTW Freiburg) demonstrated much smaller penumbra values compared to those of the CC13/PTW31010 detectors for the 30 × 30 mm2 field. There was no difference in the FWHM, unflatness, and slope parameters between the values for the CC13/PTW31010 detectors and all other detectors. OPF curves demonstrated small variations, and the relative difference from the mean value of each data point was almost within 1% for all field sizes. Although the penumbra region exhibited detector-dependent variations, all other parameters showed tiny interunit variations regardless of the detector type.

Early intervention using high-precision radiotherapy preserved visual function for five consecutive patients with optic nerve sheath meningioma.

BACKGROUND: There has been a paradigm shift in the treatment for optic nerve sheath meningioma (ONSM) from surgery to fractionated stereotactic radiotherapy (FSRT) in other countries. However, FSRT has seldom been performed in Japan. The purpose of this retrospective study is to reconfirm the effectiveness of early intervention with precision radiotherapy for ONSM reported in our previous study. METHODS: Five consecutive patients with ONSM were retrospectively analyzed. All patients underwent intensity-modulated radiotherapy (IMRT) or FSRT. They received the early interventions between 1.5 and 7 months after deterioration of the disease. The median dose was 52.8 Gy (range 46.0-59.4 Gy) and the median number of fractions was 25 (range 22-33). RESULTS: All patients experienced reestablishment of vision at the median follow-up time of 36 months (range 18-54 months). Four of them noted early improvement of visual deficits during the treatment course (range 2-4 weeks) and the remaining patient improved 3 weeks after completion of IMRT. The median tumor reduction was 53% (range 39-75%). One patient with diabetes mellitus developed retinal bleeding as a result of radiation retinopathy 16 months after IMRT, although the doses were acceptable. The remaining 4 patients have no late toxicity at the follow-up time of 31-54 months. CONCLUSIONS: A paradigm shift is necessary from surgery to early intervention using precision radiotherapy for the treatment of ONSM in Japan.

[Radiofrequency Ablation under Computed Tomography during Arterial Portography for Hypovascular Liver Metastases from Advanced Pancreatic Cancer].

A 70's man had been treated with gemcitabine(GEM)and nab-paclitaxel(nabPTX)combination for advanced pancreatic tail cancer with splenic invasion and liver metastases. However, the primary lesion was not controlled, then intensity-modulat- ed radiation therapy(76.5 Gy/17 Fr)was performed for primary lesion. Three grown hypovascular liver metastases were detected by follow-up EOB-MRI and PET-computed tomography(CT)imaging with 18F-FDG. Unfortunately, these lesions were not detected by intravenous injection of contrast media with CT nor ultrasonography. Radiofrequency ablation(RFA) under computed tomography during arterial portography(CTAP)guidance was performed. The patient has been alive for 1 year after RFA with no recurrence. CTAP could be a feasible image guidance for the treatment of hypovascular liver metastases with RFA.

Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage.

AIM: The purpose of this study was to determine the optimal mean liver biologically effective dose (BED) to prevent radiation-induced liver disease (RILD) in stereotactic body radiation therapy (SBRT). BACKGROUND: The actual mean doses appropriate for liver irradiation in modern radiotherapy techniques have not been adequately investigated, although SBRT is sometimes alternatively performed using fractionated regimens. MATERIALS AND METHODS: SBRT treatment plans for liver tumors in 50 patients were analyzed. All distributions of the physical doses were transformed to BED2 using the linear-quadratic model. The relationship between physical doses and the BED2 for the liver were then analyzed, as was the relationship between the mean BED2 for the liver and the planning target volume (PTV). RESULTS: A significantly positive correlation was observed between the mean physical dose for the background liver and the mean BED2 for the whole liver (P < 0.0001, r = 0.9558). Using the LQ model, a mean BED2 of 73 and 16 Gy for the whole liver corresponded to the hepatic tolerable mean physical dose of 21 and 6 Gy for Child-Pugh A- and B-classified patients, respectively. Additionally, the PTV values were positively correlated with the BEDs for the whole liver (P < 0.0001, r = 0.8600), and the background liver (P < 0.0001, r = 0.7854). CONCLUSION: A mean BED2 of 73 and 16 Gy for the whole liver appeared appropriate to prevent RILD in patients with Child-Pugh classes A and B, respectively. The mean BED2 for the liver correlated well with the PTV.

Clinical introduction of Monte Carlo treatment planning for lung stereotactic body radiotherapy.

The purpose of this study was to investigate the impact of Monte Carlo (MC) calculations and optimized dose definitions in stereotactic body radiotherapy (SBRT) for lung cancer patients. We used a retrospective patient review and basic virtual phantom to determine dose prescriptions. Fifty-three patients underwent SBRT. A basic virtual phantom had a gross tumor volume (GTV) of 10.0 mm with equivalent water density of 1.0 g/cm3, which was surrounded by equivalent lung surrounding the GTV of 0.25 g/cm3. D95 of the planning target volume (PTV) and D99 of the GTV were evaluated with different GTV sizes (5.0 to 30.0 mm) and different lung densities (0.05 to 0.45 g/cm3). Prescribed dose was defined as 95% of the PTV should receive 100% of the dose (48 Gy/4 fractions) using pencil beam (PB) calculation and recalculated using MC calculation. In the patient study, average doses to the D95 of the PTV and D99 of the GTV using the MC calculation plan were 19.9% and 10.2% lower than those by the PB calculation plan, respectively. In the phantom study, decreased doses to the D95 of the PTV and D99 of the GTV using the MC calculation plan were accompanied with changes GTV size from 30.0to 5.0 mm, which was decreased from 8.4% to 19.6% for the PTV and from 17.4%to 27.5% for the GTV. Similar results were seen with changes in lung density from 0.45 to 0.05 g/cm3, with doses to the D95 of the PTV and D99 of the GTV were decreased from 12.8% to 59.0% and from 7.6% to 44.8%, respectively. The decrease in dose to the PTV with MC calculation was strongly dependent on lung density. We suggest that dose definition to the GTV for lung cancer SBRT be optimized using MC calculation. Our current clinical protocol for lung SBRT is based on a prescribed dose of 44 Gy in 4 fractions to the GTV using MC calculation.

Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy.

BACKGROUND/AIM: Stereotactic body radiotherapy for prostate cancer using CyberKnife with circular cone requires a long treatment time. Raster scanning intensity modulated radiotherapy (RS-IMRT) has a potential of improving treatment efficacy, introducing shorter treatment time, better target dose uniformity, and lower organ at risk (OAR) dose. The purpose of the study was to develop a fluence optimization system for RS-IMRT. PATIENTS AND METHODS: RS-IMRT plans were created for five prostate cancer patients treated with the Novalis system and parameters were compared to the Novalis treatment plans. From 80 nodes available for the CyberKnife, twelve nodes were arbitrarily selected. On the beam's eye view of each beam, a 100×100 matrix of optimization points was created at the target center plane. The beam fluence map was optimized using the attraction-repulsion model (ARM). The beam fluence maps were converted to the scanning sequence using the ARM and a final dose calculation was performed. RESULTS: For planning target volume (PTV), RS-IMRT plans showed higher dose covering 2% of the volume (D2%) and lower D98% compared to the Novalis plans. However, the homogeneity was within our Institutional clinical protocol. The RS-IMRT plans showed significantly lower OAR dose parameters including bladder volume receiving 100% of prescribed dose (V100%) and dose delivered to 5 cm3 of rectum (D5 cc). CONCLUSION: We developed a fluence optimization system for RS-IMRT that performs the entire RS-IMRT treatment planning process, including scanning sequence optimization and final dose calculation. The RS-IMRT was capable of generating clinically acceptable plans.

＜Editors' Choice＞ Elective nodal irradiation versus involved field radiotherapy for limited disease small cell lung cancer: a single-institution experience.

Elective nodal irradiation (ENI) and involved field radiotherapy (IFRT) are definitive radiotherapeutic approaches used to treat patients with limited-disease small cell lung cancer (LD-SCLC). However, no solid consensus exists on their optimal target volume. The current study aimed to assess the clinical outcomes of patients with LD-SCLC who received definitive ENI or IFRT. A retrospective single-institution study of patients who received definitive radiotherapy between 2008 and 2020 was performed. All patients underwent whole-body positron emission tomography/computed tomography before three-dimensional conformal radiotherapy. Among the 37 patients analyzed, 22 and 15 received ENI and IFRT, respectively. The thoracic radiotherapy dose was mostly either 60 Gy in 30 fractions delivered in 2-Gy fractions once daily or 45 Gy in 30 fractions delivered in 1.5-Gy fractions twice daily. The median follow-up period was 21.4 months. A total of 12 patients (32%) experienced locoregional relapse: 10 within and 2 outside the irradiation fields. One patient in the IFRT group experienced isolated nodal failure. Differences in locoregional relapse-free, progression-free, and overall survival rates between ENI and IFRT were not significant. Overall, IFRT did not promote a significant increase in locoregional recurrence compared to ENI. Our findings suggested the utility of IFRT in standard clinical practice and support its use for patients with LD-SCLC.

Development of raster scanning IMRT using a robotic radiosurgery system.

Treatment time with the CyberKnife frameless radiosurgery system is prolonged due to the motion of the robotic arm. We have developed a novel scanning irradiation method to reduce treatment time. We generated treatment plans mimicking eight-field intensity-modulated radiotherapy (IMRT) plans generated for the Novalis radiosurgery system. 2D dose planes were generated with multiple static beam spots collimated by a fixed circular cone. The weights of the uniformly distributed beam spots in each dose plane were optimized using the attraction-repulsion model. The beam spots were converted to the scanning speed to generate the raster scanning plan. To shorten treatment time, we also developed a hybrid scanning method which combines static beams with larger cone sizes and the raster scanning method. Differences between the Novalis and the scanning plan's dose planes were evaluated with the criterion of a 5% dose difference. The mean passing rates of three cases were > 85% for cone sizes ≤ 12.5 mm. Although the total monitor units (MU) increased for smaller cone sizes in an inverse-square manner, the hybrid scanning method greatly reduced the total MU, while maintaining dose distributions comparable to those with the Novalis plan. The estimated treatment time of the hybrid scanning with a 12.5 mm cone size was on average 22% shorter than that of the sequential plans. This technique will be useful in allowing the CyberKnife with conventional circular cones to achieve excellent dose distribution with a shortened treatment time.

[Evaluation of new methods for removing moire artifact of radiochromic film].

An optical interference-pattern, a moire artifact, is produced during the film scanning process using a flatbed scanner. Images with moire artifacts include optical density fluctuations thereby leading to inaccuracy of measurement. In this study, we proposed two methods for removing moire artifacts from radiochromic film and compared dose response and profile as well as image resolution and size between our proposed methods versus the conventional process. The proposed methods could remove the artifacts without impairing dosimetric performance. It is expected that the proposed methods facilitate more accurate film dosimetry with reflective radiochromic films.

Collection and analysis of photon beam data for Varian C-series linear accelerators: a potential reference beam data set.

This study aimed to collect and analyze photon beam data for the Varian C-series linear accelerators (Varian Medical Systems, Palo Alto, CA, USA). We evaluated the potential of the average data to be used as reference beam data for the radiotherapy treatment planning system commissioning verification. We collected 20 data sets for 4 and 6 MV photon beams, and 40 data sets for a 10 MV photon beam generated by the Varian C-series machines, which contained the percent depth dose (PDD), off-center ratio (OCR), and output factor (OPF) from 20 institutions. The average for each of the data types was calculated across the 20 machines. Dose differences from the average for PDD at the dose fall-off region were less than 1.0%. Relative differences from the average for the OPF data were almost within 1.0% for all energies and field sizes. For OCR data in the flat regions, the standard deviation of the dose differences from the average was within 1.0%, excluding that of the 30 × 30 mm2 field size being approximately 1.5%. For all energies and field sizes, the distance to agreement from the average in the OCR penumbra regions was less than 1.0 mm. The average data except for the small field size found in this study can be used as reference beam data for verifying users' commissioning results.

Inter-unit variability of multi-leaf collimator parameters for IMRT and VMAT treatment planning: a multi-institutional survey.

Modern treatment machines have shown small inter-unit variability regarding beam data. Recently, vendor-provided average beam data, such as the Representative Beam Data (RBD) of the TrueBeam (Varian Medical Systems, Palo Alto, CA, USA), has been used for modeling of the Eclipse (Varian Medical Systems) treatment planning system. However, RBD does not provide multi-leaf collimator (MLC) parameters, such as MLC leaf transmission factor (LTF) and dosimetric leaf gap (DLG). We performed a web-based multi-institutional survey to investigate these parameters as well as the measurement protocols and customization of the parameters for intensity-modulated radiotherapy (IMRT) and/or volumetric modulated radiotherapy (VMAT) commissioning. We collected 69 sets of linear accelerator (linac) data from 58 institutions. In order to measure MLC parameters, most institutions used farmer-type ionization chambers with a sensitive volume of 0.6 cm3, water phantoms, source surface distance of 90 cm with 10 cm depth, and a vendor-provided plan. The LTF showed small inter-unit variabilities, although the DLG showed large variations. For optimization of the parameters for IMRT/VMAT calculations, DLG values were upwardly adjusted at many institutions, whereas the LTF values were modestly changed. We clarified that MLC parameters were measured under the same conditions at more than half of the facilities. Most institutions customized parameters in a similar manner for IMRT/VMAT. The median measured and customized values obtained in our study will be valuable to verify MLC installation accuracy and to shorten the iterative processes of finding the optimal values.

Evaluation of the Differences Between Measurements in Multiple Institutions and Calculation Modeled by Representative Beam Data in Prostate VMAT Plan.

BACKGROUND/AIM: This study aimed to investigate the potential differences between multi-institutional measurements and treatment planning system (TPS) calculation modeled by representative beam data for patient-specific quality assurance (QA), including multi-leaf collimator (MLC) parameters. MATERIALS AND METHODS: Eleven TrueBeam from nine institutions were used in this study. Volumetric arc therapy (VMAT) plan for verification was created using Eclipse. The point dose of the CC13 ionization chamber and the dose distribution of the GAFCHROMIC EBT3 film were measured and analyzed. RESULTS: Point dose differences in patient-specific QA provided a mean±standard deviation of 1.0%±0.6%. Mean gamma pass rates of dose distribution were in excess of 99% and 96% for 3%/2 mm and 2%/2 mm gamma criteria, respectively. CONCLUSION: There was good agreement between measurements and calculations, indicating the small influence of complex VMAT in the underlying processes. Therefore, implementation of the same MLC parameters on TPS among different institutions with the same planning policy should be considered to ensure consistency and efficiency in radiation treatment processes.

[Summary of the Report of Task Group 100 of the AAPM: Application of Risk Analysis Methods to Radiation Therapy Quality Management].

In 2016, the American Association of Physicists in Medicine (AAPM) has published a report of task group (TG) 100 with a completely new concept, entitled "application of risk analysis methods to radiation therapy quality management." TG-100 proposed implementation of risk analysis in radiotherapy to prevent harmful radiotherapy accidents. In addition, it enables us to conduct efficient and effective quality management in not only advanced radiotherapy such as intensity-modulated radiotherapy and image-guided radiotherapy but also new technology in radiotherapy. It should be noted that treatment process in modern radiotherapy is absolutely more complex and it needs skillful staff and adequate resources. TG-100 methodology could identify weakness in radiotherapy procedure through assessment of failure modes that could occur in overall treatment processes. All staff in radiotherapy have to explore quality management in radiotherapy safety.

Inter-institutional variability of small-field-dosimetry beams among HD120™ multileaf collimators: a multi-institutional analysis.

Detector selection and technical problems can result in large variations in small-field-dosimetry data among institutions. In this study, we evaluated inter-institutional variability in the small-field-beam data of the Novalis Tx linear accelerator (Varian Medical Systems and BrainLAB) with an HD120™ multileaf collimator. Beam data for modeling an iPLAN treatment planning system (BrainLAB) were collected from 19 institutions and median values of percentage depth doses (PDD), diagonal profiles, transversal profiles, and ratios of detector readings (detector output factors; OF det) were calculated. Inter-institutional variability was defined as the difference between the median value and the value for each machine. PDD measured with a 100 mm square field size and diagonal profiles showed only small variations; however, when measured with a 5 mm square field size, the PDD variation from the median exceeded ±2%, especially for ionization chambers. With a 10 mm square field, the variation was within approximately ±1%. The OF det variation was within ±2% for ⩾20 mm square field sizes. The maximum variation exceeded 20% for 5 mm square fields. The ionization chambers' OF det values were smaller than the median, whereas those for the EDGE detector (Sun Nuclear Corp) were larger. When the OF det values were corrected by output factor correction factors, the variation was greatly reduced, with only a few machines showing variations greater than ±5% from the median value. In conclusion, this multi-institutional investigation of small field dosimetry for HD120 multileaf collimators demonstrated some large variations in the dosimetric parameters, especially for a 5 mm square field size. Most differences were detector-dependent, and the variation was reduced when output correction factors were applied. However, variations probably due to measurement errors were also observed, indicating that careful management is needed for small-field dosimetry.

Definitive re-irradiation using intensity-modulated radiation therapy in cancers of the head and neck, focusing on rare tumors.

PURPOSE: To analyze the outcomes following re-irradiation for local recurrence of rare head and neck tumors. MATERIAL AND METHODS: We retrospectively analyzed 11 patients who had received intensity-modulated radiation therapy (IMRT) for recurrent tumors in the head and neck except for laryngopharynx. RESULTS: Primary tumor sites included the maxillary sinus, nasal cavity, and external ear canal in six, three, and two patients, respectively. The median follow-up times were 13 (range, 3-54) months. The median survival time was 17 months with 1- and 2-year survival rates of 63.64 and 39.77%, respectively. Among 11 patients, five experienced local failure in the follow-up period. The 1- and 2-year local control rates were 58 and 47%, respectively. Patients who had received a radiation dose of ≥3 Gy per fraction showed significantly better local control than those receiving less (p = .0419). One patient experienced Grade 3 facial pain as acute toxicity. Late toxicities included radiographic findings of partial central nervous system necrosis in three patients and Grade 3 osteonecrosis and Grade 3 facial nerve disorder in one patient. CONCLUSIONS: Re-irradiation of rare head and neck tumors using IMRT for loco-regional recurrence may be an acceptable treatment option.

Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer.

BACKGROUND/AIM: The long-term efficacy and safety of moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in prostate cancer remains uncertain. This study aimed to evaluate MH-IMRT regimen of 72 Gy in 30 fractions in patients with prostate cancer. PATIENTS AND METHODS: The outcomes of 412 consecutive prostate cancer patients, who received MH-IMRT between May 2007 and December 2012, were retrospectively reviewed. The median patient age was 70.9 (range=50-84) years. Late gastrointestinal (GI) and genitourinary (GU) toxicity rates were evaluated according to the CTCAE ver. 3.0. The overall survival, biochemical relapse-free survival rate (bRFS), late GI toxicity, and GU toxicity rates were analyzed with the Kaplan-Meier method. RESULTS: The median follow-up was 71.5 (range, 1.4-124.8) months. The 5-year bRFS rate was 93.2%. The 5-year grade ≥2 late GI and GU toxicity rates were 3.3% and 4.5%, respectively. CONCLUSION: MH-IMRT regimen of 72 Gy in 30 fractions was effective and safe for prostate cancer patients.

Feasibility study of a non-invasive eye fixation and monitoring device using a right-angle prism mirror for intensity-modulated radiotherapy for choroidal melanoma.

We aimed to describe the feasibility and efficacy of a novel non-invasive fixation and monitoring (F-M) device for the eyeballs (which uses a right-angle prism mirror as the optic axis guide) in three consecutive patients with choroidal melanoma who were treated with intensity-modulated radiotherapy (IMRT). The device consists of an immobilization shell, a right-angle prism mirror, a high magnification optical zoom video camera, a guide lamp, a digital voice recorder, a personal computer, and a National Television System Committee standard analog video cable. Using the right-angle prism mirror, the antero-posterior axis was determined coincident with the optic axis connecting the centers of the cornea and pupil. The axis was then connected to the guide light and video camera installed on the couch top on the distal side. Repositioning accuracy improved using this method. Furthermore, the positional error of the lens was markedly reduced from ±1.16, ±1.68 and ±1.11 mm to ±0.23, ±0.58 and ±0.26 mm in the horizontal direction, and from ±1.50, ±1.03 and ±0.48 mm to ±0.29, ±0.30 and ±0.24 mm in the vertical direction (Patient #1, #2 and #3, respectively). Accordingly, the F-M device method decreased the planning target volume size and improved the dose-volume histogram parameters of the organ-at-risk via IMRT inverse planning. Importantly, the treatment method was well tolerated.

Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer.

Metastatic liver tumors (MLTs) from colorectal cancer (CRC) are often treated with stereotactic body radiation therapy (SBRT). The present study aimed to examine the predictive factors for response of MLTs to SBRT. A total of 39 MLTs from 24 patients with CRC were retrospectively analyzed. Radiotherapy for MLT was typically performed with a prescribed dose equivalent to a biologically effective dose (BED)10 of 100 Gy. The median follow-up period was 16 months (range, 5-64 months). The median prescribed dose and total BED10 were 56 Gy (range, 45-72 Gy) and 97.5 Gy (range, 71.7-115.5 Gy), respectively, in a median of 8 fractions (range, 4-33 fractions). The 1- and 2-year local control rates were 67.2 and 35.9%, respectively. For patients with MLT treated with ablative SBRT (BED10 ≥100 Gy in ≤5 fractions), the 1- and 2-year local control rates were 83.3 and 62.5%, respectively. Univariate analysis showed that primary tumor location (left-sided colon), maximum tumor diameter (≤30 mm) and ablative SBRT (BED10 ≥100 Gy in ≤5 fractions) were significantly associated with improved local control (P=0.0058, P=0.0059 and P=0.0268, respectively). Multivariate analysis showed that tumor diameter was significantly associated with improved local control (P=0.0314). In addition, patients who received ablative SBRT had significantly prolonged overall survival times compared with those treated with non-ablative SBRT (P=0.0261). To conclude, tumors ≤30 mm that can be treated with ablative SBRT are associated with good local control rates. The primary tumor location may affect the radiosensitivity of MLTs.

Outcomes and toxicity of radiotherapy for refractory bone and soft tissue sarcomas.

Surgical resection is a well-established treatment option for sarcoma. However, anatomical barriers often hamper radical surgical procedures. The treatment of unresectable sarcoma, including local or distant failures following initial treatment, is challenging. The aim of the present study was to analyze the outcome of radiotherapy (RT) for refractory sarcoma, including unresectable, metastatic and recurrent disease, following radical treatment. We retrospectively reviewed a total of 67 tumors in 28 patients who were treated with RT between 2007 and 2014. Clinical target volume (CTV) was generally not defined in a preventive manner; therefore, in the majority of the cases, CTV equaled the gross tumor volume. The total delivered dose, number of fractions and biological equivalent dose were 52 (range, 40-69), 10 (range, 4-24) and 92.2 (range, 56-119.6) Gy, respectively. Only 1 patient developed local failure, with a median follow-up of 11 months (range, 1-59 months). Therefore, the 12-month progression-free survival rate for 67 sites was 96.8%. The overall survival rates at 12 and 36 months were 75.8 and 30.2%, respectively. A total of 2 patients developed grade >2 toxicities, including grade 3 mucositis and grade 4 pericardial effusion. Our results demonstrated that radical RT using modern techniques is highly feasible, achieves excellent local control, and may be an effective treatment option for refractory sarcoma.